During the past decade, MVZ Onkologische Kooperation Harz conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MVZ Onkologische Kooperation Harz" #1 sponsor was "AIO-Studien-gGmbH" with 2 trials, followed by "German CLL Study Group" with 2 trials sponsored, "Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest" with 2 trials sponsored, "iOMEDICO AG" with 2 trials sponsored and "AGO Research GmbH" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MVZ Onkologische Kooperation Harz" #1 collaborator was "German Breast Group" with 2 trials as a collaborator, "Roche Pharma AG" with 2 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "MVZ Onkologische Kooperation Harz" are "Breast Cancer" (2 trials), "Cholangiocarcinoma" (2 trials), "Chronic Lymphoid Leukemia" (2 trials), "Gallbladder Cancer" (2 trials) and "Hepatocellular Cancer" (2 trials). Many other conditions were trialed in "MVZ Onkologische Kooperation Harz" in a lesser frequency.

Most popular intervention types in "MVZ Onkologische Kooperation Harz" are "Drug" (7 trials), "Biological" (3 trials), "Behavioral" (1 trials), "Combination Product" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Acalabrutinib" (1 trials), "Bevacizumab" (1 trials), "Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab" (1 trials), "Carboplatin" (1 trials) and "Concomitant coaching" (1 trials). Other intervention names were less common.

The vast majority of trials in "MVZ Onkologische Kooperation Harz" are 12 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "MVZ Onkologische Kooperation Harz". undefined are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in MVZ Onkologische Kooperation Harz, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in MVZ Onkologische Kooperation Harz, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".